MGI PHARMA INC

MGI Pharma Inc. manufactures pharmaceutical preparations focused on oncology-supportive therapies, delivering injectable and oral products such as antiemetics and hematology-supportive agents to hospitals, oncology clinics, and specialty pharmacies navigating the stringent standards of SIC 2834. The company balances research-driven formulations with contract manufacturing for healthcare institutions that require consistent supplies of supportive care medicines alongside its own branded offerings. MGI’s market-facing team works directly with pharmacy directors, oncologists, and group purchasing organizations to ensure availability while educating prescribers on clinical value and dosing safety—key differentiators in a space where competition and payer reimbursement pressure are intense. Material risks include regulatory compliance, particularly FDA approvals and manufacturing inspections, the cost of meeting evolving quality standards, and reliance on limited distribution networks that can amplify shortages. Investors watch late-cycle monitoring of working capital and litigation exposures tied to product liability. CIK 702131 remains dormant on the filing front since the November 1999 Form 10-Q, so view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025